Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

The initial studies focusing on lipoprotein (a)[Lp (a)] and its role in atherosclerotic
cardiovascular disease were conducted exclusively in Whites. Subsequently, multiple large …

Calcific aortic valve stenosis (CAS), the most prevalent valvular disease worldwide, has
been demonstrated to frequently occur in conjunction with coronary artery disease (CAD) …

Background Elevated lipoprotein (a)[Lp (a)] level is an independent genetic risk factor that
increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 2–4 fold. We aimed …

Considerable differences exist amongst published guidelines for adults on the use of Lp (a)
in clinical practice, and recommendations for youth are limited. With increasing knowledge …

Aims There are inconsistent results on the association between lipoprotein (a) and mortality-
related outcomes due to a lack of evidence from large-scale observational studies of Asians …

Background A growing number of studies have demonstrated a causal association between
lipoprotein (a)[Lp (a)] and atherosclerotic cardiovascular diseases (ASCVDs), but its …

Abstract Objective Lipoprotein (a)[Lp (a)] is an atherogenic and prothrombotic lipoprotein
associated with atherosclerotic cardiovascular disease (ASCVD). We assessed the …

Abstract Lipoprotein (a)[Lp (a)] is an atherogenic lipoprotein with a strong genetic regulation.
Up to 90% of the concentrations are explained by a single gene, the LPA gene. The …

Background Inflammation and coagulation may contribute to the increased risk for
atherosclerotic cardiovascular disease (ASCVD) associated with high lipoprotein (a). The …